Search PubMed⌕ Search

Biomedical subjects

G Forsbach

Publications and source records attributed to G Forsbach.

At least 37 records · Page 2Linked to original sources
PubMed1980

Abnormal prolactin levels in serum and seminal plasma in infertile men.

The role of prolactin in male infertility was studied in 33 patients in whom serum and seminal plasma prolactin levels were determined. With the exception of those patients with Klinefelter's syndrome, infertile males presented moderate hyperprolactinemia as compared with a control group of 34 men. Prolactin levels in seminal plasma were greater than in serum in all patients studied; however, prolactin levels in infertile patients were significantly less than in normal males. Therefore, this situation is the reverse of what happens in serum. Seven patients with idiopathic oligospermia were treated with 5 mg of bromocriptine daily during 6 months, resulting in no measurable effect on the sperm count. Infertility in men may be associated with moderate hyperprolactinemia but bromocriptine is of no therapeutic use. Interpretation of the abnormal levels of prolactin in seminal plasma in oligo- and azoospermic men requires further investigation.

Adult↗
PubMed1979

The effect of pregnancy and lactation on pituitary prolactin-secreting tumours.

Management of the amenorrhoea-galactorrhoea syndrome due to pituitary tumour is still controversial. However, in cases of pituitary prolactin-producing adenomas, ovulation and pregnancy are readily induced medically with bromocriptine. In our series of 14 patients conception occurred in all cases within 6 months of treatment. All of the 14 women had uneventful full term pregnancies and normal infants. Neither neurological nor visual symptoms appeared in these patients during their pregnancies. Lactation had no apparent effect on the growth of the pituitary tumour since radiological and neurological evaluations were unchanged. Prolactin levels for each patient following the termination of pregnancy and breast feeding were apparently diminished or similar to the prolactin levels obtained prior to treatment. This finding could add to the evidence that probably there was no further growth of the pituitary tumour. Three of the 14 women have had a second pregnancy without any complications. It is recommended that patients with microadenomas can be allowed to become pregnant on bromocriptine alone, provided that they are carefully supervised during pregnancy.

Adenoma↗
PubMed1978

Bromocriptine. Clinical experience in the induction of pregnancy in amenorrhea-galactorrhea syndrome.

This study included a group of 50 women with amenorrhea-galactorrhea who were treated with bromocriptine (2-bromo-alpha-ergocryptine). Forty-two of these patients ovulated, and 36 conceived within 8 months of treatment. The pregnancies of 30 women reached a duration of 20 weeks or longer following ovulation induced by bromocriptine. Except in 1 case which ended in 10-week spontaneous abortion, the pregnancies of 26 patients terminated in 24 single, one twin, and one triplet births. All of the 29 newborns were healthy, and no congenital malformations were detected. The main side effects during treatment were transient constipation and nausea. Following delivery, return to pretreatment status was noted in all patients, which supports the fact that bromocriptine is not a curative agent.

Adult↗
PubMed1977

Gonadotropic responsiveness to clomiphene, LRH, estradiol, and bromocriptine in galactorrheic women.

Twenty hyperprolactinemic patients with galactorrhea were studied to determine their gonadotropic responses to various stimuli. Five women lacked response to gonadotropin following the administration of clomiphene citrate. Ten patients who had luteinizing hormone releasing hormone (LRH) tests before and during bromocriptine administration exhibited varied FSH and LH responses that apparently were unaffected by bromocriptine therapy. A loss of the normal positive feedback of estrogens at the level of the hypothalamus was demonstrated in most patients before and during bromocriptine therapy. Long-term treatment with bromocriptine in 11 women resulted in a decrease of serum prolactin, cessation of lactation in all, and pregnancy in 8. These results suggest that the failure of normal secretion of gonadotropins in hyperprolactinemic women may result from 1) inadequate release of endogenous LRH, and 2) loss of the positive feedback of estrogens, as a result of the same hypothalamic disturbance that provokes the hyperprolactinemia. In turn, the elevated prolactin levels may exert a short-loop negative feedback at the hypothalamic level, inhibiting cyclic gonadotropin release.

Bromocriptine↗
PubMed1977

Relationship of maternal, fetal, and amniotic fluid prolactin levels.

Serum prolactin (PRL) was measured by radioimmunoassay in 80 women in serum and amniotic fluid during various stages of normal pregnancy and at delivery. In addition, prolactin levels were measured in cord sera at 60 newborns. PRL levels in maternal serum progressively increased during pregnancy, and they were lower than the corresponding levels in amniotic fluid. A relative decline in the amniotic fluid prolactin between the 39th and the 40th week of gestation was observed. The mean concentration of PRL in umbilical blood was significant lower than that in maternal blood at delivery. The lack of correlation between the PRL in amniotic fluid and the levels found in maternal and newborns serum suggests an independient source of PRL in each of the three compartments.

Amniotic Fluid↗
PubMed1977

Anterior pituitary function during early neonatal period.

Anterior pituitary responsiveness to parturition was studied in 28 normal newborn infants. Cord blood sera samples were obtained for measurement of TSH, HGH, PRL, and FSH at birth and at intervals during four hours. The neonate infant's pituitary response to parturition consists of both PRL and TSH increments, which is probably mediated by an increase in TRH release.

Fetal Blood↗
PubMed1976

Therapeutic use of gonadoliberin (follicle-stimulating hormone/luteinizing hormone-releasing hormone) in women.

Certain conclusions may be drawn from the present review: 1. Synthetic FSH/LH-RH may induce ovulation; therefore, a therapeutic effect has been established in some cases of anovulatory infertility, but it is still difficult to assess the correct dose of FSH/LH-RH because of individual variations in response. 2. Gonadoliberin may also be used to induce ovulation after follicular maturation has been evoked by other agents. FSH/LH-RH can be utilized for supplementing the LH surge after clomiphene therapy in cases of clomiphene failure. When associated with HMG, the synthetic decapeptide may be helpful in avoiding the ovarian hyperstimulation syndrome. 3. The "triggering" of ovulation by a continuous infusion of FSH/LH-RH might be a convenient means of controlling the timing of ovulation. 4. It is expected that FSH/LH-RH blocking analogs may be used to inhibit both LH and FSH release induced by endogenous gonadoliberin in women seeking contraception.

Anovulation↗